Damora Therapeutics Announces Major Leadership and Board Overhaul

The latest announcement is out from Damora Therapeutics ( (DMRA) ).

On March 23, 2026, Damora Therapeutics announced a sweeping leadership overhaul, appointing industry veteran Jennifer Jarrett as president and chief executive officer effective March 30, 2026, and adding her to the board as a Class II director. Jarrett, a former Arcus Biosciences chief operating officer with extensive biotech, technology and investment banking experience, succeeds Sherwin Sattarzadeh as principal executive officer while he remains chief operating officer, and receives a substantial compensation package including salary, bonus eligibility and significant equity grants aligned with long-term performance and change-of-control protections.

The board also reshaped its composition, with directors Amit Munshi, Carl Goldfischer and Jayson Dallas resigning effective March 23, 2026, in moves the company said were not due to disagreements, and having their equity awards fully accelerated. That same day, Damora appointed Spyre Therapeutics chief executive Cameron Turtle and former Blueprint Medicines chief financial officer Michael Landsittel as Class III directors, installed Landsittel as audit committee chair, named existing director and Fairmount Funds partner Peter Harwin as board chair, and reduced the board’s size from seven to six members.

In parallel, Damora confirmed new offer terms for general counsel and corporate secretary Garrett Winslow, setting revised base pay, bonus targets and severance and equity-vesting protections that mirror the company’s broader effort to lock in seasoned leadership ahead of key clinical milestones. With Jarrett’s strategic and capital markets background and the addition of directors experienced in building and financing late-stage biotech companies, the governance changes are designed to support Damora’s push to advance its lead program DMR-001 and broader pipeline in mutant calreticulin-driven myeloproliferative neoplasms, potentially strengthening its competitive position in the blood disorders market.

The most recent analyst rating on (DMRA) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Damora Therapeutics stock, see the DMRA Stock Forecast page.

Spark’s Take on DMRA Stock

According to Spark, TipRanks’ AI Analyst, DMRA is a Neutral.

The score is held back primarily by weak fundamentals (no revenue, ongoing losses, and continued cash burn despite improvement) and unattractive earnings-based valuation (negative P/E). Offsetting factors include strong technical momentum (price above key moving averages with positive MACD) and positive corporate developments (Damora acquisition and associated financing extending runway).

To see Spark’s full report on DMRA stock, click here.

More about Damora Therapeutics

Damora Therapeutics, Inc. is a Boston-based biotechnology company focused on developing a new generation of biologic therapies for hematologic disorders, particularly mutant calreticulin-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. The Nasdaq-listed firm aims to deliver best-in-class, disease-modifying treatments that offer broad mutation coverage and improved convenience for patients, with multiple programs scheduled to enter clinical development in 2026.

The company positions itself at the intersection of oncology and hematology innovation, targeting areas of significant unmet medical need in blood disorders. Its lead program, DMR-001, anchors a pipeline intended to redefine standards of care for patients with mutCALR-driven MPNs, underpinned by what management describes as a strong balance sheet and an increasingly experienced leadership and board.

Average Trading Volume: 224,464

Technical Sentiment Signal: Buy

Current Market Cap: $1.09B

For a thorough assessment of DMRA stock, go to TipRanks’ Stock Analysis page.